Search
Research
A population pharmacokinetic study of benzathine benzylpenicillin G administration in children and adolescents with rheumatic heart diseaseFew children and adolescents receiving BPG as secondary prophylaxis will achieve concentrations >0.02 mg/L for the majority of the time between injections
Research
Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart DiseaseRheumatic heart disease affects more than 40.5 million people worldwide and results in 306,000 deaths annually. Echocardiographic screening detects rheumatic heart disease at an early, latent stage. Whether secondary antibiotic prophylaxis is effective in preventing progression of latent rheumatic heart disease is unknown.
Research
Evolution, Evidence and Effect of Secondary Prophylaxis Against Rheumatic FeverThe association between group A streptococcal infection and rheumatic fever (RF) was established in the early 20th century.
Research
Rheumatic heart disease in Indigenous children in northern Australia: Differences in prevalence and the challenges of screeningThis study compared regional differences in the prevalence of rheumatic heart disease in Indigenous Australian children, and describes the logistical and...
Research
Supply of benzathine penicillin G: the 20-year experience in AustraliaReliable supplies of BPG are essential for delivering the recommended schedule of secondary prophylaxis for people living with RHD.
News & Events
National honour for The Kids DirectorLeading paediatrician, infectious diseases specialist and Executive Director of The Kids Research Institute Australia, Professor Jonathan Carapetis, has been recognised for his significant contribution towards medical research with the award of Member of the Order of Australia (AM).
News & Events
Ending deadly heart disease finally within our sightsIt's been a huge year for those working to eliminate rheumatic heart disease (RHD), with breakthroughs including $35M in funding to develop a Strep A vaccine.
News & Events
Finding answers for Tenaya: from a sore throat to open-heart surgeryWhen Katrina took her daughter Tenaya to the local emergency department for the fourth time, she was determined she wouldn’t be leaving without answers.
News & Events
$35 million to develop vaccine with potential to save half a million lives per yearA vaccine to prevent rheumatic heart disease (RHD) and other life-threatening conditions caused by the common Strep A bacteria is a step closer thanks to funding announced by Minister for Indigenous Health, Hon Ken Wyatt AM, MP, in Perth today.
Research
Prospects for the future: supporting the elimination of rheumatic heart disease – a National Heart, Lung, and Blood Institute Workshop ProceedingsJonathan Carapetis AM AM MBBS FRACP FAFPHM PhD FAHMS Executive Director; Co-Head, Strep A Translation; Co-Founder of REACH 08 6319 1000 contact@